University of Texas Southwestern Medical Center, Dallas (United States of America)
Follow
Contributor content
Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
